Commercial-stage manufacturing key for CDMOs as biotech funding pullback continues, Fujifilm Diosynth CEO says

On the back of re­duced fund­ing in ear­ly clin­i­cal-stage as­sets, CD­MOs need to strength­en their com­mer­cial, large-scale man­u­fac­tur­ing ca­pa­bil­i­ties for 2024 in what looks like an­oth­er chal­leng­ing year for man­u­fac­tur­ers, Fu­ji­film Diosynth CEO Lars Pe­tersen said.

“I think the biggest hur­dle is how to ad­just to the slow­down of ven­ture cap­i­tal­ists fund­ing star­tups. It will come back, but when it’ll come back — no­body knows,” Pe­tersen told End­points News in an in­ter­view. “[Fu­ji­film Diosynth] es­pe­cial­ly sees large-scale com­mer­cial boom­ing, there is still a huge de­mand…and it’s of­ten from com­pa­nies who al­ready have a rev­enue, and they don’t nec­es­sar­i­ly need a lot of ven­ture cap­i­tal­ist fund­ing,” he ex­plained.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.